BioSpace News Archive

New England Biolabs (NEB) recently launched the NEBNext Immune Sequencing Kits, available for either human or mouse samples, to nable B-cell and/or T-cell repertoire (BCR and/or TCR) analysis of infections.

Dacryocystitis refers to an inflammation of the lacrimal gland (tear sac). It is caused due to obstruction within the nasolacrimal duct and subsequent stagnation in the lacrimal sac.

Drug development is a process, which focuses on identifying a compound therapeutically helpful in treating and curing diseases.

Nanotechnology is used in medicine to manipulate the molecule and develop new materials and devices.

BlueSphere Bio announces the appointment of Jonathan Peacock as Chairman of the Board of Directors in its pursuit to build an industry leading Board and executive team

The global narcolepsy drugs market generated $2,429 million in 2018, and is projected to reach $5,360 million by 2026, growing at a CAGR of 10.3% from 2019 to 2026.

Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), today announced a new initiative with Drake University and Certintell to drive improved health outcomes and demonstrate the value of combining remote patient monitoring (RPM) and comprehensive medication management, including MedWise® Medication Safety Reviews (MSRs) throughout rural Iowa.

Today, GetMyDNA announces the launch of their consumer-initiated Pharmacogenetics at-home test kit. Pharmacogenetics (PGx) testing measures the body’s response to specific drugs.

Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced the initial launch and first implantations of the Fuse Orbitum™ Compression Staple.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma.